{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006627","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.235606+00:00","generated_at":"2026-06-09T01:26:27.557818+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M","bullets":["Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.","Net loss $36.1M ($0.19/share) vs $42.5M ($0.23) in Q3 2022; operating cash use $16.5M (-43.9% yoy).","Full-year 2023 ORLADEYO revenue guidance reaffirmed at no less than $320M; peak revenue target $1B.","R&D expenses down 11% yoy to $46.9M due to program discontinuations; SG&A up 37% to $50.7M on ORLADEYO launch.","Cash and investments $399.2M at Sep 30, 2023; debt interest expense rose on Pharmakon facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006627","json":"https://secwatch.observer/filing/0001171843-23-006627.json","markdown":"https://secwatch.observer/filing/0001171843-23-006627.md","text":"https://secwatch.observer/filing/0001171843-23-006627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/0001171843-23-006627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/f8k_110223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:26:27.557818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a783d1e8e55326dca1ee7d7ecd0aa5b524703bc","claim":"BIOCRYST PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $86.7 million, net income $36.1 million, or $0.19 per share. Guidance reaffirmed.","evidence_excerpt":"in the investors section of the company website at www.biocryst.com. Third Quarter 2023 Financial Results For the three months ended September 30, 2023, total revenues were $86.7 million, compared to $75.8 million in the third quarter of 2022 (+14.4 percent y-o-y). The increase was primarily due to an increase in ORLADEYO net revenue of $19.7 million, partially","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323006627/0001171843-23-006627-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$86.7 million"},{"label":"Net income","value":"$36.1 million, or $0.19 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}